Inventor · disambiguated record
Frank Hilberg
Also filed as: HILBERG FRANK
11 granted patents·19 pending applications·291 citations·filing 2000–2021
91Inventor score
Files withBOEHRINGER INGELHEIM INT12BOEHRINGER INGELHEIM PHARMA11STEFANIC MARTIN FRIEDRICH2VAN RYN JOANNE2LARSEN ANNETTE1
Top patents by PatentIndex Score
30 records- 0197US6762180B1Substituted indolines which inhibit receptor tyrosine kinasesBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Jul 13, 2004·129 cites·8 claims
- 0296US7846936B2Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesisBOEHRINGER INGELHEIM INT·Filed 2008·Granted Dec 7, 2010·42 cites·5 claims
- 0396US7547703B2Indoline derivatives substituted in the 6-position, their preparation and their use as medicamentsBOEHRINGER INGELHEIM PHARMA·Filed 2006·Granted Jun 16, 2009·28 cites·9 claims
- 0491US7119093B23-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical compositionBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Oct 10, 2006·41 cites·7 claims
- 0588US7989474B2Use of Lck inhibitors for treatment of immunologic diseasesBOEHRINGER INGELHEIM PHARMA·Filed 2008·Granted Aug 2, 2011·14 cites·2 claims
- 0683US7148249B2Indolinones substituted by heterocycles, the preparation thereof and their use as medicamentsBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Dec 12, 2006·21 cites·7 claims
- 0777US7169936B2Indolinone derivatives substituted in the 6-position, their preparation and their use as medicamentsBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Jan 30, 2007·6 cites·4 claims
- 0875US6858641B2Substituted indolinonesBOEHRINGER INGELHEIM PHARMA·Filed 2002·Granted Feb 22, 2005·9 cites·9 claims
- 0972US11198726B2Anti-cancer combination therapyBOEHRINGER INGELHEIM INT·Filed 2018·Granted Dec 14, 2021·1 cites·6 claims
- 1068US7858616B2Indolinone derivatives substituted in the 6 position, their preparation and their use as medicamentsBOEHRINGER INGELHEIM PHARMA·Filed 2009·Granted Dec 28, 2010·0 cites·4 claims
- 1166US2011178099A1Pharmaceutical combinationBOEHRINGER INGELHEIM INT·Filed 2009·Application pending·0 cites
- 1262US2014057898A1Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesisSTEFANIC MARTIN FRIEDRICH·Filed 2013·Application pending·0 cites
- 1361US2009306104A1Use of Lck inhibitors for treatment of immunologic diseasesBOEHRINGER INGELHEIM PHARMA·Filed 2009·Application pending·0 cites
- 1461US2018243308A1Pharmaceutical combinationBOEHRINGER INGELHEIM INT·Filed 2018·Application pending·0 cites
- 1561US2022340651A1Anti cancer combination therapyBOEHRINGER INGELHEIM INT·Filed 2021·Application pending·0 cites
- 1659US2014187563A1Combination therapy in treatment of oncological and fibrotic diseasesVAN RYN JOANNE·Filed 2014·Application pending·0 cites
- 1758US2013237549A1Pharmaceutical combinationSTEFANIC MARTIN FRIEDRICH·Filed 2013·Application pending·0 cites
- 1858US2005043233A1Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesisBOEHRINGER INGELHEIM INT·Filed 2004·Application pending·0 cites
- 1957US2011039863A1Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesisBOEHRINGER INGELHEIM INT·Filed 2010·Application pending·0 cites
- 2057US2011136826A1Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesisBOEHRINGER INGELHEIM INT·Filed 2010·Application pending·0 cites
- 2156US2015265610A1Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesisBOEHRINGER INGELHEIM INT·Filed 2015·Application pending·0 cites
- 2256US2011171289A1Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesisBOEHRINGER INGELHEIM INT·Filed 2010·Application pending·0 cites
- 2355US2016250218A1Pharmaceutical combinationBOEHRINGER INGELHEIM INT·Filed 2016·Application pending·0 cites
- 2453US2004204458A1Use of Lck inhibitors for treatment of immunologic diseasesBOEHRINGER INGELHEIM PHARMA·Filed 2003·Application pending·0 cites
- 2552US2015174126A1Pharmaceutical combinationBOEHRINGER INGELHEIM INT·Filed 2015·Application pending·0 cites
- 2652US2006258681A13-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical compositionROTH GERALD J·Filed 2006·Application pending·0 cites
- 2748US2003162796A1Pharmaceutical composition for the treatment of disorders of non-human mammalsFiled 2002·Application pending·0 cites
- 2842US7514468B2Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositionsBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Apr 7, 2009·0 cites·18 claims
- 2941US2012142703A1New combination therapy in treatment of oncological and fibrotic diseasesVAN RYN JOANNE·Filed 2010·Application pending·0 cites
- 3033US2012157472A1Method for treating colorectal cancerLARSEN ANNETTE·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Frank Hilberg files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →